[go: up one dir, main page]

ATE318141T1 - Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen - Google Patents

Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen

Info

Publication number
ATE318141T1
ATE318141T1 AT98937635T AT98937635T ATE318141T1 AT E318141 T1 ATE318141 T1 AT E318141T1 AT 98937635 T AT98937635 T AT 98937635T AT 98937635 T AT98937635 T AT 98937635T AT E318141 T1 ATE318141 T1 AT E318141T1
Authority
AT
Austria
Prior art keywords
taurolidine
taurultam
production
medicinal product
preventing metastases
Prior art date
Application number
AT98937635T
Other languages
English (en)
Inventor
Rolf Pfirrmann
Original Assignee
Geistlich Soehne Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Soehne Ag filed Critical Geistlich Soehne Ag
Application granted granted Critical
Publication of ATE318141T1 publication Critical patent/ATE318141T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Materials For Medical Uses (AREA)
AT98937635T 1997-07-31 1998-07-31 Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen ATE318141T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9716219.2A GB9716219D0 (en) 1997-07-31 1997-07-31 Prevention of metastases

Publications (1)

Publication Number Publication Date
ATE318141T1 true ATE318141T1 (de) 2006-03-15

Family

ID=10816777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937635T ATE318141T1 (de) 1997-07-31 1998-07-31 Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen

Country Status (7)

Country Link
EP (1) EP1001781B1 (de)
JP (2) JP2001511463A (de)
AT (1) ATE318141T1 (de)
DE (1) DE69833554T2 (de)
ES (1) ES2255172T3 (de)
GB (1) GB9716219D0 (de)
WO (1) WO1999006114A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626795D0 (en) 1996-12-23 1997-02-12 Geistlich Soehne Ag Combating infection in delivery systems
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US7132413B1 (en) 1997-07-31 2006-11-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Anticoagulant/sterilizing compositions and methods
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
CA2302720C (en) * 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
CA2393252A1 (en) 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors
CN100519525C (zh) 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
WO2003028642A2 (en) * 2001-10-01 2003-04-10 Rhode Island Hospital, A Lifespan Partner Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
US8236794B2 (en) 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
WO2008029264A2 (en) * 2006-09-07 2008-03-13 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treating bone cancer
AU2019331913B2 (en) * 2018-08-31 2025-06-26 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
GB9400163D0 (en) * 1994-01-06 1994-03-02 Geistlich Soehne Ag Membrane
DE19606897C2 (de) * 1996-02-13 2002-08-29 Geistlich Soehne Ag Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren

Also Published As

Publication number Publication date
DE69833554D1 (de) 2006-04-27
ES2255172T3 (es) 2006-06-16
JP2001511463A (ja) 2001-08-14
EP1001781B1 (de) 2006-02-22
JP2010215615A (ja) 2010-09-30
EP1001781A2 (de) 2000-05-24
DE69833554T2 (de) 2006-08-10
WO1999006114A2 (en) 1999-02-11
GB9716219D0 (en) 1997-10-08
WO1999006114A3 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
ATE318141T1 (de) Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen
WO1998016523A3 (en) Selective factor xa inhibitors
WO2000071493A3 (en) INHIBITORS OF FACTOR Xa
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
ZA9710796B (en) Oxyiminopregnanecarbolactones.
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
DK0883405T3 (da) Aminoproteaseinhibitorer
ATE390130T1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
WO1996040743A3 (en) Inhibitors of factor xa
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
SE9600216D0 (sv) Styrning av läkningsprocesser
ATE267597T1 (de) Verwendung von polycyclischen 2-amino-thiazol systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
ATE273006T1 (de) Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
SE9802209D0 (sv) Novel compounds
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
WO2001014576A3 (en) Process and intermediates for the preparation of isoxazolecaroxamides and analogues
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
ATE232723T1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE324111T1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1001781

Country of ref document: EP